344 related articles for article (PubMed ID: 36100784)
1. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
Chen M; Li S; Huang M; Guo J; Huang X; Guo W; Chen L; Lin Y; Jacobs L; Wang C; Fu F
Breast Cancer Res Treat; 2022 Nov; 196(2):267-277. PubMed ID: 36100784
[TBL] [Abstract][Full Text] [Related]
2. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
3. The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.
Cavalcante FP; Zerwes FP; Souza ABA; Ziegelmann PK; Alcantara R; Cardoso A; Mattar A; Millen EC; Frasson AL
Eur J Surg Oncol; 2024 Mar; 50(3):107967. PubMed ID: 38262300
[TBL] [Abstract][Full Text] [Related]
4. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
Cabıoğlu N; Karanlık H; Kangal D; Özkurt E; Öner G; Sezen F; Yılmaz R; Tükenmez M; Önder S; İğci A; Özmen V; Dinççağ A; Engin G; Müslümanoğlu M
Ann Surg Oncol; 2018 Oct; 25(10):3030-3036. PubMed ID: 29978371
[TBL] [Abstract][Full Text] [Related]
5. Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.
Chavda J; Mishra A; Silodia A; Yadav SK; Sharma DB; Sharma D; Khandare M
Breast Cancer Res Treat; 2022 May; 193(1):105-110. PubMed ID: 35246773
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
7. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
10. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
Breast J; 2022; 2022():1507881. PubMed ID: 36051467
[TBL] [Abstract][Full Text] [Related]
11. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
12. Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.
Zhang GC; Liao N; Guo ZB; Qian XK; Ren CY; Yao M; Li XR; Wang K; Zu J
Clin Transl Oncol; 2013 Jan; 15(1):79-84. PubMed ID: 22926944
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced ultrasonography and blue dye methods in detection of sentinel lymph nodes following neoadjuvant chemotherapy in initially node positive breast cancer.
Wu X; Tang L; Huang W; Huang S; Peng W; Hu D
Arch Gynecol Obstet; 2020 Sep; 302(3):685-692. PubMed ID: 32602000
[TBL] [Abstract][Full Text] [Related]
14. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
16. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.
Takahashi M; Jinno H; Hayashida T; Sakata M; Asakura K; Kitagawa Y
World J Surg; 2012 Dec; 36(12):2847-52. PubMed ID: 22806206
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence.
Resende HM; Lichtenfels M; Soares IC; Renó AACL; Cunha AP; Falcão PG; Pieroni CSP; Assis BR; Cardoso P; Marassi PHA; Reis RDS
Acta Cir Bras; 2021; 36(6):e360608. PubMed ID: 34231654
[TBL] [Abstract][Full Text] [Related]
19. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
20. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
